. Author manuscript; available in PMC: 2018 Aug 1.

Published in final edited form as: J Rheumatol. 2017 Mar 15;44(8):1184–1189. doi: 10.3899/jrheum.160185

Table 2.

Relative Risk of Incident PE and DVT According to SjS Status

	SjS	Non-SjS
	N=1,175	N=11,947
PE
Cases, N	14	36
Incidence Rate/1000 Person-Years	3.85	0.89
Age-, Sex-, Entry Time-Matched Cox HR (95% CI)	5.57 (2.90, 10.68)	1.00
^* Fully-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)	4.07 (2.04, 8.09)	1.00
DVT
Cases, N	10	32
Incidence Rate/1000 Person-Years	2.75	0.79
Age-, Sex-, Entry Time-Matched Cox HR (95% CI)	4.04 (1.95, 8.40)	1.00
^* Fully-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)	2.80 (1.27, 6.17)	1.00
VTE
Cases, N	19	58
Incidence Rate/1000 Person-Years	5.24	1.44
Age-, Sex-, Entry Time-Matched Cox HR (95% CI)	4.24 (2.48, 7.26)	1.00
^* Fully-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)	2.92 (1.66, 5.16)	1.00

Fully adjusted models include the following selected covariates: for PE, hormone replacement therapy, no. outpatient visits and glucocorticoids; DVT, glucocorticoids and no. outpatient visits; PE or DVT, glucocorticoids and no. outpatient visits. PE: pulmonary embolism; DVT: deep vein thrombosis; SjS: Sjögren syndrome; VTE: venous thromboembolism.